Table 3. Preference and reasons to choose human papillomavirus (HPV) vaccines (bivalent vs. quadrivalent) in practice for adolescent girls aged 10–17 years.
| n | %a | ||||
| Bivalent - Cervarix® | 116 | 28.0 | |||
| Quadrivalent - Gardasil® | 128 | 30.9 | |||
| No preference | 170 | 41.1 | |||
| Extremely or very important | Important | Fairly important | Somewhat important | Not at all important | |
| Stronger protection | 138 (61.1) | 49 (21.7) | 14 (6.2) | 8 (3.5) | 17 (7.5) |
| Safety | 134 (51.2) | 79 (30.2) | 23 (8.8) | 8 (3.1) | 18 (6.9) |
| Lower price | 67 (27.9) | 73 (30.4) | 39 (16.3) | 18 (7.5) | 43 (17.9) |
| More HPV types | 138 (53.5) | 53 (20.5) | 19 (7.4) | 17 (6.6) | 31 (12.0) |
| Protect genital warts | 108 (44.6) | 51 (21.1) | 23 (9.5) | 21 (8.7) | 39 (16.1) |
| Better antibody response | 145 (55.6) | 63 (24.1) | 23 (8.8) | 12 (4.6) | 18 (6.9) |
| Long-lasting immunity | 141 (56.8) | 63 (25.4) | 19 (7.7) | 8 (3.2) | 17 (6.9) |
| Cross-protection for other cancer-associated HPV types | 139 (53.4) | 78 (30.0) | 18 (6.9) | 7 (2.7) | 18 (6.9) |
| Better adjuvant | 86 (34.4) | 80 (32.0) | 36 (14.4) | 12 (4.8) | 36 (14.4) |
| Patients think it’s better | 86 (33.4) | 73 (28.4) | 36 (14.0) | 20 (7.8) | 42 (16.3) |
| Practice management | 66 (26.8) | 78 (31.7) | 27 (11.0) | 15 (6.1) | 60 (24.4) |
| Selected by Government | 79 (30.6) | 88 (34.1) | 29 (11.2) | 19 (7.4) | 43 (16.7) |
| Credibility of manufacturer | 68 (28) | 85 (35.0) | 29 (11.9) | 22 (9.1) | 39 (16.0) |
| Comprehensive service of manufacturer | 68 (29.2) | 74 (31.8) | 27 (11.6) | 24 (10.3) | 40 (17.2) |
a
Percentages in brackets were valid % which excluded missing variables.